These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25828363)

  • 1. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
    Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
    Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
    Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
    Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent absence of HER2 expression, regardless of HER2 amplification status, in neuroendocrine carcinomas of the stomach.
    Ishida M; Sekine S; Taniguchi H; Fukagawa T; Katai H; Kushima R
    Histopathology; 2014 Jun; 64(7):1027-31. PubMed ID: 24329753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer.
    Saito T; Nakanishi H; Mochizuki Y; Ito S; Ito Y; Misawa K; Yatabe Y; Yamamichi K; Kondo E
    Gastric Cancer; 2015 Oct; 18(4):711-9. PubMed ID: 25173363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
    Zhang H; Wang Y; Wang Y; Wu D; Lin E; Xia Q
    Pathol Res Pract; 2020 Nov; 216(11):153229. PubMed ID: 33010699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?
    Selcukbiricik F; Erdamar S; Buyukunal E; Serrdengecti S; Demirelli F
    Asian Pac J Cancer Prev; 2014; 15(24):10607-11. PubMed ID: 25605147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
    Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
    Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
    Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
    Nadaf AS; Rani H; Dinesh US
    Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas.
    Cho EY; Park K; Do I; Cho J; Kim J; Lee J; Kim S; Kim KM; Sohn TS; Kang WK; Kim S
    Mod Pathol; 2013 May; 26(5):677-84. PubMed ID: 23238628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
    Hedner C; Tran L; Borg D; Nodin B; Jirström K; Eberhard J
    Histopathology; 2016 Jan; 68(2):230-40. PubMed ID: 26016514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
    Bozzetti C; Negri FV; Lagrasta CA; Crafa P; Bassano C; Tamagnini I; Gardini G; Nizzoli R; Leonardi F; Gasparro D; Camisa R; Cavalli S; Silini EM; Ardizzoni A
    Br J Cancer; 2011 Apr; 104(9):1372-6. PubMed ID: 21487407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dual-color silver-enhanced in-situ hybridization for determination of HER2 gene amplification in gastric carcinoma].
    Fan D; Li Y; Ran W; Yu W; Li H
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):4-7. PubMed ID: 24713241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
    Lee HE; Park KU; Yoo SB; Nam SK; Park DJ; Kim HH; Lee HS
    Eur J Cancer; 2013 Apr; 49(6):1448-57. PubMed ID: 23146959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.